New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
08:00 EDTACT, HITK, IPXL, MNK, MNTA, PRGO, RDY, TEVABMO Capital to hold a summit
BMO Generic Drug Summit is being held in Orlando on February 19.
News For ACT;HITK;IPXL;MNK;MNTA;PRGO;RDY;TEVA From The Last 14 Days
Check below for free stories on ACT;HITK;IPXL;MNK;MNTA;PRGO;RDY;TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 16, 2014
07:59 EDTPRGOTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 15, 2014
17:10 EDTIPXLImpax receives subpoena related to digoxin sales
Subscribe for More Information
11:13 EDTTEVA, PRGOPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
07:48 EDTPRGOPerrigo could be acquired, says RBC Capital
After Globes suggested that Perrigo has hired an investment bank to sell the company. RBC Capital thinks the company has several attributes that could appeal to potential acquirers, including its ability to serve as an inversion vehicle. However, the firm believes that Perrigo could also acquire another company instead. RBC Capital keeps a $160 price target and Outperform rating on the shares.
07:35 EDTPRGOPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
July 14, 2014
16:30 EDTPRGOOn The Fly: Closing Wrap
Subscribe for More Information
15:09 EDTMNKQuestcor rises after S-4 effective, interest from other suitors disclosed
Subscribe for More Information
10:49 EDTPRGOPerrigo hires bank, seeks merger with large peer, Globes says
Subscribe for More Information
10:48 EDTPRGOPerrigo calls active on circulation of Globes report
Perrigo July 145, 150 and 155 calls are active on total call volume of 1500 contracts (300 puts) following the circulation of Globes report. July call option implied volatility 50, August is at 40, November is at 31; compared to its 26-week average of 29 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:38 EDTPRGOPerrigo move higher attributed to circulation of Globes report
Subscribe for More Information
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
07:04 EDTMNKMallinckrodt and Questcor update transaction
Mallinckrodt (MNK) and Questcor (QCOR) announced that the registration statement on Form S-4 filed with the SEC by Mallinckrodt on May 16 and amended on July 11 which includes a joint proxy statement of Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, was declared effective on July 11. The companies have also each scheduled shareholder meetings on August 14 for shareholders of record on July 9 to consider (i) in the case of Mallinckrodt, its proposal to issue its ordinary shares in connection with its proposed acquisition of Questcor and (ii) in the case of Questcor, approval of the merger agreement with Mallinckrodt and related matters. The transaction is currently expected to be completed in August.
July 11, 2014
16:31 EDTACTActavis confirms generic Diclegis patent challenge
Subscribe for More Information
10:00 EDTPRGOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:15 EDTPRGOPerrigo downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
06:39 EDTMNKQuestcor reports Acthar adverse effects data, NY Times says
The number of patients who reported an adverse effect last year while taking Questcor's (QCOR) Acthar drug amounted to almost 5% of prescriptions dispensed, the company stated in a regulatory filing released yesterday, according to The New York Times. The filing marked the first time that the company has disclosed any difficulties experienced by Acthar patients, the newspaper added. Questcor has agreed to be bought by Mallinckrodt (MNK). Reference Link
July 10, 2014
10:46 EDTPRGOPerrigo management to meet with Guggenheim
Meeting to be held in New York on July 16 hosted by Guggenheim.
July 9, 2014
07:15 EDTTEVATeva, others fined $583.4M by EU regulators, Reuters says
Subscribe for More Information
06:49 EDTACT, TEVAGeneric drug prices have risen significantly, NY Times says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use